Invivyd (IVVD) Assets Average (2021 - 2025)
Invivyd posted quarterly Assets Average of $208.0 million for Q4 2025, up 42.76% year-on-year from $145.7 million in Q4 2024, and up 82.24% on a QoQ basis from $114.1 million in Q3 2025.
Invivyd (IVVD) has 5 years of Assets Average data on file, last reported at $208.0 million in Q4 2025.
- For the quarter ending Q4 2025, Assets Average rose 42.76% year-over-year to $208.0 million; the trailing twelve-month figure through Dec 2025 stood at $208.0 million (up 42.76% YoY), and the FY2025 full-year result was $203.2 million, up 13.3% from the prior year.
- Assets Average for Q4 2025 stood at $208.0 million, up from $114.1 million in the prior quarter.
- Across five years, Assets Average topped out at $653.2 million in Q4 2021 and bottomed at $96.4 million in Q2 2025.
- The 5-year median for Assets Average is $273.6 million (2023), against an average of $315.5 million.
- Peak annual rise in Assets Average reached 42.76% in 2025, while the deepest fall reached 50.9% in 2025.
- A 5-year view of Assets Average shows it stood at $653.2 million in 2021, then tumbled by 38.16% to $404.0 million in 2022, then tumbled by 37.6% to $252.0 million in 2023, then tumbled by 42.19% to $145.7 million in 2024, then soared by 42.76% to $208.0 million in 2025.
- The last three Assets Average figures came in at $208.0 million (Q4 2025), $114.1 million (Q3 2025), and $96.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 208.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 208.02 Mn |
| Sep 30, 2025 | 114.15 Mn |
| Jun 30, 2025 | 96.44 Mn |
| Mar 31, 2025 | 116.63 Mn |
| Dec 31, 2024 | 145.72 Mn |
| Sep 30, 2024 | 169.63 Mn |
| Jun 30, 2024 | 196.41 Mn |
| Mar 31, 2024 | 222.32 Mn |
| Dec 31, 2023 | 252.05 Mn |
| Sep 30, 2023 | 295.17 Mn |
| Jun 30, 2023 | 332.99 Mn |
| Mar 31, 2023 | 366.87 Mn |
| Dec 31, 2022 | 403.96 Mn |
| Sep 30, 2022 | 454.68 Mn |
| Jun 30, 2022 | 520.44 Mn |
| Mar 31, 2022 | 588.18 Mn |
| Dec 31, 2021 | 653.18 Mn |
| Sep 30, 2021 | 542.13 Mn |